RBC Bioscience Corporation(TW:6848)
NT$20.95+0.80 (+3.97%)
TW:6848
RBC Bioscience Corporation financials statements
NT$20.95
At close:+0.80 (+3.97%)
RBC Bioscience Corporation (6848) Financial Statements
RBC Bioscience Corporation Financial Overview
RBC Bioscience Corporation's market cap is currently NT$299.02M. The company's EPS TTM is NT$1.48; its P/E ratio is 14.15; and it has a dividend yield of 22.60%. RBC Bioscience Corporation has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | NT$ 219.71M | NT$ 205.25M | NT$ 172.47M | NT$ 173.89M | NT$ 251.18M |
| Gross Profit | NT$ 92.59M | NT$ 98.07M | NT$ 72.89M | NT$ 73.01M | NT$ 117.07M |
| Operating Income | NT$ 35.03M | NT$ 35.80M | NT$ 14.54M | NT$ 7.75M | NT$ 48.61M |
| EBITDA | NT$ 51.12M | NT$ 55.35M | NT$ 37.07M | NT$ 32.12M | NT$ 62.31M |
| Net Income | NT$ 23.54M | NT$ 21.57M | NT$ 6.43M | NT$ 3.78M | NT$ 28.73M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | NT$ 36.44M | NT$ 81.13M | NT$ 65.18M | NT$ 76.64M | NT$ 126.47M |
| Total Assets | NT$ 724.49M | NT$ 763.88M | NT$ 753.79M | NT$ 790.55M | NT$ 847.60M |
| Total Debt | NT$ 391.17M | NT$ 478.47M | NT$ 471.64M | NT$ 481.75M | NT$ 510.99M |
| Net Debt | NT$ 354.73M | NT$ 398.61M | NT$ 422.19M | NT$ 428.53M | NT$ 449.27M |
| Total Liabilities | NT$ 455.95M | NT$ 514.58M | NT$ 513.08M | NT$ 541.73M | NT$ 590.77M |
| Stockholders' Equity | NT$ 268.54M | NT$ 249.30M | NT$ 240.71M | NT$ 248.81M | NT$ 256.83M |
| Cash Flow | |||||
| Free Cash Flow | NT$ 34.08M | NT$ 45.61M | NT$ 6.74M | NT$ -3.44M | NT$ -475.42M |
| Operating Cash Flow | NT$ 40.52M | NT$ 55.93M | NT$ 13.21M | NT$ 6.60M | NT$ -25.30M |
| Investing Cash Flow | NT$ -15.43M | NT$ -9.37M | NT$ 1.00M | NT$ 12.61M | NT$ -425.67M |
| Financing Cash Flow | NT$ -68.52M | NT$ -31.88M | NT$ -24.96M | NT$ -40.75M | NT$ 424.49M |
Currency in TWD
